diagnost tool
quest quietli execut well despit tough
environ fit nice large-cap incom
portfolio buy pt
may sexiest compani coverag dividend
yield nearli free cash flow improv test volum help compani
beat year bp despit reimburs cut pama
could eas new bill becom law quest deliv better-than-expect volum
market share gain plan like unit health consist call view
quest underappreci cash cow well posit consolid lab
hospit lab market competit edg lh view
continu view on-going pama cut base case new lab act could spell
relief lh reiter buy rais pt use
reason multipl roll forward new adj ep estim
adj ep beat rev
y/i beat volum beat
driven organ volum
expand network access share gain expect increas
throughout revenue /req better
includ pama hit
new lab act revers pama pain investor prudenc warrant
assum chang statu quo pama pain cautious optimist
potenti new lab act bill introduc hous last month
could possibl delay next round data report one year
expand scope applic lab includ hospit lab would
result better reimburs lh bill mark progress made acla
view odd pama fix zero view lab act free call option
pama fix
mark tailwind volum growth quest gain health plan access
live anthem horizon georgia quest size
increment billion revenu opportun second quest expect continu
grow funnel full expect deal third quest
drive cost structur invigor target cost save
reiter guid beat street estim top-lin
bottom-lin compani reiter revenue guid
y/i adj ep guid greater assum volum increas
throughout year complet look like exceed
midpoint revenu guid
model tick rev y/i bump
rev y/i rais penni adj ep
adj ep initi revenue adj
ep estim y/i estim exclud
announc yet assum chang expect pama cut
price close busi juli
largest clinic lab us
focus routin gene-bas esoter test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
reiter buy rate rais pt
use multipl new adj ep estim formerli
pt use multipl adj ep estim
lab act look alter cours pama note quit
variabl outstand rate come next pama period would
take effect believ lh stock continu price
statu quo on-going pama cut encourag introduct
lab act hous delay next round pama data report one year
lab act look provid applic laboratori addit time report
privat payer data requir neutral third parti recommend congress
improv pama data collect rate set process
push retail quest expect expand footprint expand access directli
consum end locat safeway store
quest indic call expand footprint store
beyond state tx fl wal-mart store see path
quest direct aim make easier patient get test want
similar initi awar well privately-held binx health
quest live quest direct provid individu abil
log onto quest order one test without consult
physician individu schedul time come patient servic center
psc simpli come without appoint provid sampl test
manag indic offer alreadi well receiv particularli
among millenni though clarifi age quest call demand std test
includ ct/ng syphili total std panel expand std
panel includ std test hcv hbv test addit test
includ cbc panel cholesterol drug screen panel gluten
recent select one prefer lab unit unitedhealthcar
announc select quest ameripath/dermpath subsidiari
labcorp lh biorefer lab genedx invita mayo clinic
lab join newli creat prefer lab network pln effect juli
pln seek steer member get lowest cost test best qualiti
ie reduc wait time servic on-line schedul lab measur
quarterli perform indic unclear impact part
pln might indic price remain
work in-network lab think sinc oper prefer
lab network think addit volum come name better
care servic lower price
acquisit deal stay quest remain activ involv sever
health system evalu hospit outreach strategi revenu guid
continu assum point growth includ point
alreadi announc seem grow awar
low base financi impact pama hospit outreach lab
expect ramp consolid lab ad point
growth vs growth sum
acquisit cost
chang long-term target look drive revenu growth compound-annual-growth-rate
earn growth exclud benefit share
buyback remind quest novemb lower four-year earn
growth target compound-annual-growth-rate mid-to-high-singl digit cite headwind
reimburs pama carryov test
headwind hcvg vit wage inflat highlight challeng year
ahead view
possibl expans quest manag remain activ involv larg
hospit oper quest help lower lab spend
colorado believ expans quest work across unit state
buy unchang target price juli
diagnost tool
would mark materi posit catalyst price stock
view
in-network statu extend commerci cover
live us indic expect organ volum growth build year
primarili new live target opportun time
build revenu pharma custom newer clinic trial connect
program expect lower cost structur offset
expect reimburs impact see opportun
consolid six immuno-assay provid one opportun
buy unchang target price juli
diagnost tool
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price juli
diagnost tool
canaccord genuiti estim compani report
buy unchang target price juli
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin juli et
date time product juli et
pt use multipl adj ep estim y/i
laboratori corpor america hold lh
pt use multipl adj ep estim
risk achiev target price valuat
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
buy unchang target price juli
diagnost tool
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
